← All Sponsors
SPONSOR

Orbus Therapeutics, Inc.

Total Trials
1
Recruiting
1
Phases
Phase 1
Conditions studied: Glioblastoma, IDH-wildtypeGlioblastomaGlioblastoma MultiformeGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeGBMAstrocytomaAstrocytoma, IDH-Mutant
NCT05879367 Phase 1
Recruiting

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Glioblastoma, IDH-wildtype
United States View Trial →